Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives

A new library of 1,2,3-triazole-incorporated 1,3,4-oxadiazole-triazine derivatives (9a-j) was designed, synthesized, and tested in vitro for anticancer activity against PC3 and DU-145 (prostate cancer), A549 (lung cancer), and MCF-7 (breast cancer) cancer cell lines using the MTT assay with etoposid...

Descripción completa

Detalles Bibliográficos
Autores principales: Oggu, Sujana, Akshinthala, Parameswari, Katari, Naresh Kumar, Nagarapu, Laxmi Kumari, Malempati, Srimannarayana, Gundla, Rambabu, Jonnalagadda, Sreekantha Babu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189396/
https://www.ncbi.nlm.nih.gov/pubmed/37206039
http://dx.doi.org/10.1016/j.heliyon.2023.e15935
_version_ 1785043077849677824
author Oggu, Sujana
Akshinthala, Parameswari
Katari, Naresh Kumar
Nagarapu, Laxmi Kumari
Malempati, Srimannarayana
Gundla, Rambabu
Jonnalagadda, Sreekantha Babu
author_facet Oggu, Sujana
Akshinthala, Parameswari
Katari, Naresh Kumar
Nagarapu, Laxmi Kumari
Malempati, Srimannarayana
Gundla, Rambabu
Jonnalagadda, Sreekantha Babu
author_sort Oggu, Sujana
collection PubMed
description A new library of 1,2,3-triazole-incorporated 1,3,4-oxadiazole-triazine derivatives (9a-j) was designed, synthesized, and tested in vitro for anticancer activity against PC3 and DU-145 (prostate cancer), A549 (lung cancer), and MCF-7 (breast cancer) cancer cell lines using the MTT assay with etoposide as the control drug. The compounds exhibited remarkable anticancer activity, with IC50 values ranging from 0.16 ± 0.083 μM to 11.8 ± 7.46 μM, whereas the positive control ranged from 1.97 0.45 μM to 3.08 0.135 μM. Compound 9 d with a 4-pyridyl moiety shown exceptional anticancer activity against PC3, A549, MCF-7, and DU-145 cell lines, with IC50 values of 0.17 ± 0.063 μM, 0.19 ± 0.075 μM, 0.51 ± 0.083 μM, and 0.16 ± 0.083 μM, respectively.
format Online
Article
Text
id pubmed-10189396
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101893962023-05-18 Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives Oggu, Sujana Akshinthala, Parameswari Katari, Naresh Kumar Nagarapu, Laxmi Kumari Malempati, Srimannarayana Gundla, Rambabu Jonnalagadda, Sreekantha Babu Heliyon Research Article A new library of 1,2,3-triazole-incorporated 1,3,4-oxadiazole-triazine derivatives (9a-j) was designed, synthesized, and tested in vitro for anticancer activity against PC3 and DU-145 (prostate cancer), A549 (lung cancer), and MCF-7 (breast cancer) cancer cell lines using the MTT assay with etoposide as the control drug. The compounds exhibited remarkable anticancer activity, with IC50 values ranging from 0.16 ± 0.083 μM to 11.8 ± 7.46 μM, whereas the positive control ranged from 1.97 0.45 μM to 3.08 0.135 μM. Compound 9 d with a 4-pyridyl moiety shown exceptional anticancer activity against PC3, A549, MCF-7, and DU-145 cell lines, with IC50 values of 0.17 ± 0.063 μM, 0.19 ± 0.075 μM, 0.51 ± 0.083 μM, and 0.16 ± 0.083 μM, respectively. Elsevier 2023-05-03 /pmc/articles/PMC10189396/ /pubmed/37206039 http://dx.doi.org/10.1016/j.heliyon.2023.e15935 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Oggu, Sujana
Akshinthala, Parameswari
Katari, Naresh Kumar
Nagarapu, Laxmi Kumari
Malempati, Srimannarayana
Gundla, Rambabu
Jonnalagadda, Sreekantha Babu
Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
title Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
title_full Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
title_fullStr Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
title_full_unstemmed Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
title_short Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
title_sort design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-triazine derivatives
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189396/
https://www.ncbi.nlm.nih.gov/pubmed/37206039
http://dx.doi.org/10.1016/j.heliyon.2023.e15935
work_keys_str_mv AT oggusujana designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives
AT akshinthalaparameswari designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives
AT katarinareshkumar designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives
AT nagarapulaxmikumari designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives
AT malempatisrimannarayana designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives
AT gundlarambabu designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives
AT jonnalagaddasreekanthababu designsynthesisanticancerevaluationandmoleculardockingstudiesof123triazoleincorporated134oxadiazoletriazinederivatives

Ejemplares similares